Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?
about
Progresses towards safe and efficient gene therapy vectorsStructure of neurotropic adeno-associated virus AAVrh.8.Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine modelsHigh-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivoTargeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors.Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft modelEnhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo.Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variantsCapsid Mutated Adeno-Associated Virus Delivered to the Anterior Chamber Results in Efficient Transduction of Trabecular Meshwork in Mouse and RatVitreal delivery of AAV vectored Cnga3 restores cone function in CNGA3-/-/Nrl-/- mice, an all-cone model of CNGA3 achromatopsiaSingle point mutation in adeno-associated viral vectors -DJ capsid leads to improvement for gene delivery in vivoReprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of CancerAAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypesSite-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In VivoPerspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene TherapyEfficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors.Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector.Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus VectorsStrategies to generate high-titer, high-potency recombinant AAV3 serotype vectorsAAV-mediated transduction and targeting of retinal bipolar cells with improved mGluR6 promoters in rodents and primates.Microglia-specific targeting by novel capsid-modified AAV6 vectors.Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo.Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.BDNF treatment and extended recovery from optic nerve trauma in the catHigh-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing.Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approachSafety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).Adeno-associated virus structural biology as a tool in vector development.Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors.Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy.Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced DosesReduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNSGeneration of Helper Plasmids Encoding Mutant Adeno-associated Virus Type 2 Capsid Proteins with Increased Resistance against Proteasomal Degradation.Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo.Long-term retinal cone rescue using a capsid mutant AAV8 vector in a mouse model of CNGA3-achromatopsia.
P2860
Q26781432-99C3B0D3-6015-4013-9EDA-14ABADE06DB7Q30152836-E20B1155-B018-4B92-856F-D9F1C6E2B074Q30490945-EB53D796-8E8D-4FC9-A50B-21FFB8B09E5FQ33623549-4908D5BD-BE30-460E-A288-7CB559021226Q34629995-11400A4E-D82D-4E9B-937F-159F6D2887BFQ34700925-C713B479-0D60-4598-B144-50C91FC62B89Q34729878-B009AB46-5170-4759-8F84-43DFAA473700Q34991117-189AED84-42E0-4E56-9513-0347CE62C423Q35210473-9AC81452-5575-439E-8AC5-450ECB7CFFE7Q35656153-C27B0EBC-97D4-4046-854D-C3976AB8D6A2Q35693904-9D548FBD-16C8-4879-9E94-52B2610E8824Q35884767-13E54E55-4ECF-42AD-A3CF-56ACE38FD76EQ35949356-585908D4-90DE-4826-A537-03A0A91227C9Q36106408-CDA1C057-4AA7-4D9B-8A98-0DFAADE1C19BQ36367714-10A344CF-3098-4791-98F3-71445AB495D8Q36406869-8C2D69D4-9178-4EFC-85AE-2CA2C1BEC4B8Q36427096-A0A6AED5-58CF-49BA-B3C6-5E96B4F3CE89Q36732799-7D5F2752-6563-41CC-9858-79F130E1A884Q36736418-DA726472-4976-4B2C-9DFF-337E61E1772EQ36867801-45AC07B2-5195-48BD-B94E-252460894B20Q36890213-49FAAB99-595B-4EE9-90D5-E9D59E4E54F1Q37007749-1EC4AAD6-F00D-4301-948B-8BA81BCE6935Q37011792-628B5B3F-BE9C-4AFB-9170-3999D49600EDQ37043507-8184AC08-19CA-4C4F-9DE8-EF2AF874937CQ37243123-AC86129D-4127-4C92-8401-21C70FF0BD85Q37349186-0C46091B-F07E-402E-B524-7DC3382F7591Q37432588-FDAE3370-ACC8-4BE2-B31C-B846A7B96943Q38168940-CC4C7967-A2FB-4CED-B5DE-62161B51287EQ38188560-AE878070-59CB-49C2-ADD1-8442239383F2Q38191212-3A6A41D4-2BDF-41CB-9306-AC14F7876F5AQ38843995-884813D7-A8C9-47FC-89C4-28E012FFFB71Q39064354-4F4AB898-531E-4BFC-9209-A6B6E9C5C22CQ39409371-33852E69-E74B-4499-B4E1-02EE60638526Q40363171-05F047E4-28CC-4A4C-B048-04C6FDD00D2CQ40644650-F10630A0-495C-42F0-9160-D0E1FA86E813Q40814049-CDF6AE63-4B94-4335-A62B-CD0ABBE0F43DQ41647072-6A9B9046-D86A-4187-A45C-8DE724494D7CQ41820481-54F60FBE-A281-4F4C-AB42-ECE3D8A41E83Q42243339-782B10E2-3EC5-4B8D-9429-94292B59FFA9Q45874397-5968C8C6-1F2C-491E-A1C5-B640135F167C
P2860
Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Optimization of the capsid of ...... vectors: the final threshold?
@ast
Optimization of the capsid of ...... vectors: the final threshold?
@en
Optimization of the capsid of recombinant adeno-associated virus 2
@nl
type
label
Optimization of the capsid of ...... vectors: the final threshold?
@ast
Optimization of the capsid of ...... vectors: the final threshold?
@en
Optimization of the capsid of recombinant adeno-associated virus 2
@nl
prefLabel
Optimization of the capsid of ...... vectors: the final threshold?
@ast
Optimization of the capsid of ...... vectors: the final threshold?
@en
Optimization of the capsid of recombinant adeno-associated virus 2
@nl
P2093
P2860
P50
P1433
P1476
Optimization of the capsid of ...... vectors: the final threshold?
@en
P2093
Arun Srivastava
Lakshmanan Govindasamy
Liujiang Song
Luis Ortiz
Mavis Agbandje-McKenna
Mengqun Tan
P2860
P304
P356
10.1371/JOURNAL.PONE.0059142
P407
P577
2013-03-19T00:00:00Z